[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Jäger M, Schultheis A, Westhoff B, Krauspe R: Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96). Anticancer Res; 2005 Mar-Apr;25(2A):947-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96).
  • BACKGROUND: Since the first trial of chemotherapy in patients with osteosarcoma the survival rate has gradually improved.
  • For more than two decades, most osteosarcoma patients from Germany, Austria and Switzerland have been treated according to the protocols of the Cooperative Osteosarcoma Study Group (COSS).
  • The uniform treatment concept of a high-dose polychemotherapy pre- and postoperatively improved the survival rate of these patients significantly.
  • One severe side-effect of COSS chemotherapy is multiple osteonecrosis.
  • PATIENTS AND METHODS: In this study the osteogenic stem cell potency of three different tissue types was elucidated after COSS-96 chemotherapy (high-risk arm).
  • Mononuclear cells were obtained from the periosteum, cartilage and bone marrow of a 17-year-old female with a chondroblastic osteosarcoma.
  • The cells were cultivated for 4 weeks in standard medium and stimulated for osteogenic differentiation after the second passage with dexamethasone, glycerolphosphate and ascorbine acid.
  • Compared to other donor tissues and localizations, the fibula periosteum showed significantly higher osteoblast rates in vitro, whereas collagen II, CD34 and CD45 were not expressed in any culture.
  • CONCLUSION: The results of this study demonstrate the survival of mesenchymal progenitor cells in bone marrow during COSS-96 polychemotherapy, which allows for an osteogenic regeneration in vitro and potentially in vivo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Mesenchymal Stromal Cells / cytology. Mesenchymal Stromal Cells / drug effects. Osteosarcoma / drug therapy. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Cartilage / cytology. Cartilage / drug effects. Cell Differentiation / drug effects. Cell Survival / drug effects. Chondroblastoma / drug therapy. Chondroblastoma / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Neoadjuvant Therapy. Periosteum / cytology. Periosteum / drug effects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868932.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Ziewacz JE, Song JW, Blaivas M, Yang LJ: Radiation-induced meningeal osteosarcoma of tentorium cerebelli with intradural spinal metastases. Surg Neurol Int; 2010;1:14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced meningeal osteosarcoma of tentorium cerebelli with intradural spinal metastases.
  • We encountered a patient with a radiation-induced meningeal osteosarcoma with metastatic spread.
  • CASE DESCRIPTION: A 54-year-old man presented with a 2-week history of nausea, vomiting, and ataxia.
  • The patient underwent complete resection of the tumor with adjuvant chemotherapy.
  • Histopathologic analysis revealed chondroblastic osteosarcoma.
  • Tumor recurrence was observed 9 months after initial diagnosis, and adjuvant radiation therapy was administered.
  • CONCLUSION: Meningeal osteosarcomas are rare lesions that can metastasize and should be considered in the differential diagnosis for dural-based lesions, especially in the case of previous radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1998 Oct;40(1):87-96 [9874190.001]
  • [Cites] J Neurosurg. 2004 Dec;101(6):1061-4 [15597771.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(7):684-9 [9265963.001]
  • [Cites] J Neurooncol. 1997 May;32(3):209-13 [9049882.001]
  • [Cites] Eur J Radiol. 1992 Oct;15(3):193-5 [1490442.001]
  • [Cites] Vet Pathol. 1995 Mar;32(2):204-7 [7771066.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):965-6 [7696174.001]
  • [Cites] Acta Neuropathol. 1994;88(4):384-8 [7839833.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):793-7 [1855179.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Jul-Aug;7(4):729-32 [3088951.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):21-6 [3543236.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1244-55 [3855683.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2762-70 [2160317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 May;7(5):593-5 [6944301.001]
  • [Cites] Am J Surg Pathol. 1981 Mar;5(2):203-8 [6939339.001]
  • [Cites] Can J Surg. 1977 Nov;20(6):530-6 [271036.001]
  • [Cites] Acta Neuropathol. 1973 Feb 19;23(3):187-99 [4348056.001]
  • [Cites] Cancer. 1971 Nov;28(5):1087-99 [5288429.001]
  • [Cites] J Neurosurg. 1976 Jan;44(1):92-5 [1059735.001]
  • [Cites] Cancer. 1975 May;35(5):1405-11 [1122489.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jan;44(1):29-32 [14959934.001]
  • [Cites] BMC Cancer. 2002 Dec 3;2:34 [12464160.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):488-92; discussion 492 [12182789.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1960-2 [11733332.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):418-20 [11474278.001]
  • [Cites] Vet Pathol. 2000 Nov;37(6):653-5 [11105956.001]
  • [Cites] Arch Pathol Lab Med. 1998 Aug;122(8):737-9 [9701337.001]
  • (PMID = 20657695.001).
  • [ISSN] 2152-7806
  • [Journal-full-title] Surgical neurology international
  • [ISO-abbreviation] Surg Neurol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2908355
  • [Keywords] NOTNLM ; Meninges osteosarcoma / Radiation therapy / Spinal metastasis / Tentorium cerebelli
  •  go-up   go-down


3. Okada A, Hatori M, Hosaka M, Watanuki M, Itoi E: Secondary osteosarcoma arising after treatment for childhood hematologic malignancies. Ups J Med Sci; 2009;114(4):249-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary osteosarcoma arising after treatment for childhood hematologic malignancies.
  • Secondary osteosarcoma arising after the treatment of hematologic malignancies other than Hodgkin's lymphoma is rare.
  • We report two cases of secondary osteosarcoma arising after treatment for childhood hematologic malignancies (non-Hodgkin's lymphoma and lymphoblastic leukemia).
  • He received chemotherapy, radiation, and bone-marrow transplantation and then was in complete remission.
  • At 6 years, he complained of increasing pain of the right thigh and was diagnosed with osteoblastic osteosarcoma.
  • He received chemotherapy, radiation, and peripheral blood stem cell transplantation (PBSCT).
  • He was diagnosed with chondroblastic osteosarcoma.
  • We should rule out secondary osteosarcoma at the abnormal elevation of ALP during clinical follow-up of patients after treatment of childhood hematologic malignancies.
  • [MeSH-major] Bone Neoplasms / etiology. Hematologic Neoplasms / therapy. Neoplasms, Second Primary / etiology. Osteosarcoma / etiology
  • [MeSH-minor] Adult. Alkaline Phosphatase / blood. Biomarkers, Tumor / blood. Child. Humans. Lymphoma, T-Cell / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1972 Oct;54(7):1479-89 [4510800.001]
  • [Cites] Eur J Surg Oncol. 2009 Oct;35(10):1030-6 [19232880.001]
  • [Cites] Skeletal Radiol. 1982;8(4):279-83 [6293097.001]
  • [Cites] J Clin Pathol. 1987 Apr;40(4):398-403 [3584482.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Tumori. 1987 Aug 31;73(4):331-6 [3477902.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):193-201 [1985716.001]
  • [Cites] Oncology (Williston Park). 1991 May;5(5):135-41; discussion 142, 147-8 [1831995.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):275-81 [1729013.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Eur J Radiol. 2001 Jun;38(3):235-48 [11399379.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2074-9; discussion 2079-81 [11597387.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1959-66 [11745271.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Oct;24(7):572-4 [12368699.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):318-21 [12402067.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(5):353-9 [12634726.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Clin Chim Acta. 1991 Sep 14;201(1-2):27-33 [1790624.001]
  • [Cites] J Bone Joint Surg Am. 1992 Aug;74(7):1079-83 [1522094.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1224-30 [8435797.001]
  • [Cites] Ann Clin Biochem. 1993 Jul;30 ( Pt 4):355-72 [8379650.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] Oncology. 1996 Jul-Aug;53(4):275-80 [8692530.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):370-7 [9663598.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1169-74 [16054775.001]
  • [Cites] Cancer. 1979 Jun;43(6):2178-81 [287547.001]
  • (PMID = 19961270.001).
  • [ISSN] 2000-1967
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  • [Other-IDs] NLM/ PMC2852780
  •  go-up   go-down


Advertisement
4. Donaldson ME, Geist JR, Daley TD: Osteosarcoma of the jaws in children. Int J Paediatr Dent; 2004 Jan;14(1):54-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of the jaws in children.
  • Two cases of osteosarcoma of the jaws in children are reported.
  • She was found to have chondroblastic osteosarcoma extending through the left maxillary alveolar process and sinus.
  • Following surgery and chemotherapy, the patient has been free of disease for 7 years.
  • The second patient, an 8-year-old boy, was diagnosed with juxtacortical (parosteal) osteosarcoma of the mandible, which is a less aggressive variant of the neoplasm.
  • It is believed that this is the youngest patient reported to date with juxtacortical osteosarcoma of the jaws.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14706029.001).
  • [ISSN] 0960-7439
  • [Journal-full-title] International journal of paediatric dentistry
  • [ISO-abbreviation] Int J Paediatr Dent
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Vasilevska V, Zafirovski G, Kirjas N, Muratovska O, Janevska V, Samardziski M, Kostadinova-Kunovska S, Tolevska V, Andonovska D, Sapova B: High-grade surface osteosarcoma - chondroblastic type. Prilozi; 2007 Dec;28(2):211-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade surface osteosarcoma - chondroblastic type.
  • We present the case of an 8-year-old boy with pain in the distal part of the right thigh that occurred after a ball injury, without haematoma or oedema.
  • The plain film showed exostosis of the distal part of the right femur.
  • In another institution the "exostosis-like" formation was surgically removed and the histological finding was an aggressive type of chondroblastoma.
  • Radiography showed a large dense mass at the level of distal femoral metadiaphysis with tumour matrix mineralization, and Codman's sign.
  • Computed tomography showed a large soft tissue mass, which arose from the surface of the underlying cortical bone and signs of high-grade malignancy.
  • After operative treatment - seq.
  • Campanacci, histology showed high-grade surface osteosarcoma of chondroblastic type.
  • Pre- and post-operative chemotherapy was carried out.
  • High-grade surface osteosarcoma has the worst prognosis, compared with other surface osteosarcomas.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18356791.001).
  • [ISSN] 0351-3254
  • [Journal-full-title] Prilozi
  • [ISO-abbreviation] Prilozi
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Kumaravelu C, Sathya Kumar D, Chakravarthy C, Kishore Kumar RV, Rajasekhar G, Gokul Chandra Reddy M, Sridhar Reddy K: Chondroblastic osteosarcoma of maxilla: a case report and review of literature. J Maxillofac Oral Surg; 2009 Sep;8(3):290-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondroblastic osteosarcoma of maxilla: a case report and review of literature.
  • Craniofacial osteosarcoma is a relatively rare entity comprising about 6.5-7% of all osteosarcomas, whereas it is reported to be one of the most common malignancies of long bones.
  • We present a case of chondroblastic variant of osteosarcoma (COS) of the maxilla in an 18 year-old-girl.
  • She was treated with a subtotal maxillectomy and later referred for adjuvant chemotherapy.
  • The relevant review of literature with regard to clinical, radiographic findings, histopathological similarities to Chondrosarcoma (CS), role of Immunohistochemistry (IHC) and management modalities of Osteosarcoma of jaw bones (OSJ) in comparison with Osteosarcoma of the long bones (OSL) are being presented in this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 1988 Jan;46(1):85-7 [3422276.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1986 Aug;62(2):179-84 [3462614.001]
  • [Cites] J Maxillofac Surg. 1985 Aug;13(4):158-66 [3860594.001]
  • [Cites] Radiol Clin North Am. 1970 Dec;8(3):425-43 [4923904.001]
  • [Cites] Cancer. 1967 Mar;20(3):377-91 [5228026.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2311-6 [6573939.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):363-7 [8996163.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Apr;91(4):445-51 [11312461.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Mar;63(3):311-8 [15742279.001]
  • [Cites] J Orthop Sci. 1998;3(5):287-94 [9732564.001]
  • [Cites] Cancer Treat Res. 1993;62:269-77 [7682088.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):198-204 [9180230.001]
  • [Cites] Br J Oral Maxillofac Surg. 1997 Oct;35(5):357-62 [9427446.001]
  • (PMID = 23139529.001).
  • [ISSN] 0972-8279
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3454240
  • [Keywords] NOTNLM ; Bone neoplasm / Maxilla / Osteosarcoma
  •  go-up   go-down


7. Barut F, Kandemir NO, Ozdamar SO, Gul S, Bektas S, Gun BD, Bahadir B: Gliosarcoma with chondroblastic osteosarcomatous differentation: report of two case with clinicopathologic and immunohistochemical features. Turk Neurosurg; 2009 Oct;19(4):417-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliosarcoma with chondroblastic osteosarcomatous differentation: report of two case with clinicopathologic and immunohistochemical features.
  • Our objective is to describe clinical, morphological and immunohistochemical features of two cases of gliosarcoma with chondroblastic osteosarcomatous differentiation and to discuss its pathogenetic mechanisms.
  • The case had radiotherapy and chemotherapy postoperatively.
  • Histopathologic examination of the postmortem biopsy revealed neoplasm displaying a biphasic morphologic pattern including both gliomatous and sarcomatous components.
  • CASE 2: The case was a 69-year-old male patient with a right frontal lobe mass histologically diagnosed as gliosarcoma displaying sarcomatous and glial components.
  • We report two cases with an extremely rare histopathological diagnosis of "gliosarcoma with features of chondroblastic osteosarcoma".
  • [MeSH-major] Brain Neoplasms / pathology. Chondroblastoma / pathology. Gliosarcoma / pathology. Osteosarcoma / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847765.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


8. Bertoni F, Bacchini P, Staals EL, Davidovitz P: Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer; 2005 Jun 1;103(11):2373-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute.
  • BACKGROUND: Dedifferentiated parosteal osteosarcoma (DPOS) is a variant of osteosarcoma in which a high-grade sarcoma coexists with a conventional parosteal osteosarcoma (c-POS), either at presentation (synchronous type) or at the time of recurrence (metachronous type).
  • METHODS: In a series of 120 patients with parosteal osteosarcoma who were seen at the Rizzoli Institute from 1958 to 2000, the authors identified 29 patients who were diagnosed with DPOS.
  • The authors reviewed the clinical and radiologic features, histologic sections, treatments, and outcomes in this group of patients with DPOS.
  • Histologically, the dedifferentiated component was high-grade osteoblastic osteosarcoma in 14 patients, fibroblastic osteosarcoma in 10 patients, giant cell-rich osteosarcoma in 3 patients, and chondroblastic osteosarcoma in 2 patients.
  • Twenty-eight patients underwent surgery, and 18 of those patients received chemotherapy (5 patients received neoadjuvant chemotherapy, and 13 patients received adjuvant).
  • Of the nine patients who died, one patient received no treatment, five patients underwent surgery (with three patients achieving adequate margins) in combination with chemotherapy, and three patients underwent surgery only (with adequate margins achieved).
  • Of the 20 patients who remained alive, 13 patients underwent surgery (with 10 patients achieving adequate margins) in combination with chemotherapy, whereas 7 patients underwent surgery only (all with adequate margins).
  • [MeSH-major] Bone Neoplasms / pathology. Cell Differentiation. Osteosarcoma, Juxtacortical / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852358.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Bacri D, Arush MW, Vlodavsky E, Kollander Y, Militianu D, Postovsky S: Osteogenic sarcoma in a child with familial expansile osteolysis syndrome: an accidental association? J Pediatr Hematol Oncol; 2010 Mar;32(2):e50-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic sarcoma in a child with familial expansile osteolysis syndrome: an accidental association?
  • We present the first reported case of a child with familial expansile osteolysis syndrome (FEO) who developed osteogenic sarcoma (OS) of the iliac bone.
  • Biopsy of the patient's mass revealed chondroblastic OS.
  • Chemotherapy consisted of HD-MTX, ifosfomide, doxorubicin, and cisplatin.
  • Complete resection of the tumor was carried out, but the patient subsequently developed metastatic disease and died (histologic response to neoadjuvant chemotherapy-85%).
  • The patient's alkaline phosphatase level that was highly elevated before the start of chemotherapy, dropped significantly during treatment, with repeated elevation soon after definitive surgery, while he was recuperating and not on treatment.
  • We speculate that chemotherapy affected not only the malignant cells of OS but normal osteoblasts as well, with a decreasing level of alkaline phosphatase even in the absence of any clinical and radiographic signs of OS.
  • [MeSH-major] Bone Neoplasms / genetics. Osteolysis / genetics. Osteosarcoma / genetics. Receptor Activator of Nuclear Factor-kappa B / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Polyostotic osteolytic dysplasia, hereditary expansile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168251.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / TNFRSF11A protein, human; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


10. Fernandes R, Nikitakis NG, Pazoki A, Ord RA: Osteogenic sarcoma of the jaw: a 10-year experience. J Oral Maxillofac Surg; 2007 Jul;65(7):1286-91
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic sarcoma of the jaw: a 10-year experience.
  • Head and neck OS are associated with a lower metastatic rate than long bone OS, and they have a better 5-year survival rate, ranging between 27% and 84%.
  • The main histologic subtype was chondroblastic (8 cases), followed by osteoblastic (4 cases).
  • Overall, the primary treatment modality consisted of surgery in all 14 patients treated at the University of Maryland; 2 patients opted for treatment at other institutions.
  • Chemotherapy, consisting primarily of cisplatin and Adriamycin (doxorubicin hydrochloride; Pharmacia, Kalamazoo, MI), was used as adjuvant treatment in 4 cases of high-grade OS.
  • [MeSH-major] Jaw Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577490.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Romeo E, Gisserot O, de Jaureguiberry JP, Desse N, Souraud JB, Salem N, Faivre A, Bouvier C, Bertucci F: Meningeal chondroblastic osteosarcoma: case report and review of the literature. J Neurooncol; 2010 Nov;100(2):305-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal chondroblastic osteosarcoma: case report and review of the literature.
  • We report a case of a 51-year-old man with a chondroblastic osteosarcoma treated with pre-operative embolization, surgical removal, followed by adjuvant chemotherapy and radiation therapy.
  • [MeSH-major] Meningeal Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for chondroblastic osteosarcoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Jan;15(1):363-7 [8996163.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jan;44(1):29-32 [14959934.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Jul-Aug;7(4):729-32 [3088951.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):965-6 [7696174.001]
  • [Cites] Neurosurgery. 2000 Aug;47(2):447-50; discussion 450-1 [10942019.001]
  • [Cites] Sarcoma. 2000;4(3):119-23 [18521290.001]
  • [Cites] Clin Neuropathol. 2009 Mar-Apr;28(2):96-100 [19353840.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):56-61 [9001266.001]
  • [Cites] BMC Cancer. 2002 Dec 3;2:34 [12464160.001]
  • [Cites] Eur J Radiol. 1992 Oct;15(3):193-5 [1490442.001]
  • [Cites] Virchows Arch. 2009 Jan;454(1):81-7 [19050913.001]
  • [Cites] Am J Surg Pathol. 1981 Mar;5(2):203-8 [6939339.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(7):684-9 [9265963.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):87-96 [9874190.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):418-20 [11474278.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):488-92; discussion 492 [12182789.001]
  • (PMID = 20431908.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


12. Salamanca J, Dhimes P, Pinedo F, Gómez de la Fuente E, Pérez Espejo G, Martínez-Tello FJ: Extraskeletal cutaneous chondroblastic osteosarcoma: a case report. J Cutan Pathol; 2008 Feb;35(2):231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal cutaneous chondroblastic osteosarcoma: a case report.
  • Extraskeletal osteosarcoma is an uncommon neoplasm that usually arises in the deep soft tissues, especially in the lower extremities, with rare cases involving the subcutis or dermis.
  • Although osteoid or bone was not observed, a diagnosis of cutaneous chondroblastic osteosarcoma was suggested after excluding an origin in bone or other primary tumor sites by imaging techniques.
  • Histopathologic features of the surgical specimen were characteristic, with a predominant high-grade chondroid component together with focal fibrosarcomatous zones, areas of multinucleated giant cells and foci of bone and osteoid formation.
  • The patient underwent postoperative chemotherapy and is currently alive with pulmonary metastases 15 months after surgery.
  • In summary, we report a unique case of cutaneous osteosarcoma of the chondroblastic subtype, diagnosed on incisional skin biopsy despite the absence of osteoid or bone during tumor sampling.
  • [MeSH-major] Osteosarcoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Thigh / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190451.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


13. Krajekian J, Goode R, Papageorge MB: Chondroblastic osteosarcoma: case presentation. J Mass Dent Soc; 2001;50(3):44-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondroblastic osteosarcoma: case presentation.
  • The prognosis of jaw osteosarcoma is better with early diagnosis and radical surgery.
  • The prognosis is also improved with adjunctive radiation and chemotherapy.
  • [MeSH-major] Maxillary Neoplasms / pathology. Osteosarcoma / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11695148.001).
  • [ISSN] 0025-4800
  • [Journal-full-title] Journal of the Massachusetts Dental Society
  • [ISO-abbreviation] J Mass Dent Soc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Modarressi Ghavami SA, Lombardi T, Becker M, Richter M: [Chondroblastic osteosarcoma of the mandible: a case report with 14 years follow-up]. Rev Stomatol Chir Maxillofac; 2006 Nov;107(5):380-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chondroblastic osteosarcoma of the mandible: a case report with 14 years follow-up].
  • INTRODUCTION: Osteosarcoma, the second most frequent primary malignant bone tumor, is usually found in long bones: femur, tibia or humerus with only 6 to 7% of cases occurring in the jaws.
  • Patients with osteosarcoma of the mandible usually complain of a swelling, which can be painful or not, accompanied by paresthesia of one of the trigeminal nerve branches in about 20% of cases.
  • OBSERVATION: We report a case of chondroblastic osteosarcoma of the mandible affecting a 33-year-old woman with 14 years follow-up illustrating the difficulties of a rapid diagnosis.
  • DISCUSSION: The prognosis of osteosarcoma of the mandible relies on its histological grade and the amount of time elapsing from diagnosis to treatment onset.
  • The treatment of choice is radical surgery providing a 5-year survival rate up to 80%.
  • The definitive surgical treatment is usually performed only after several interventions because operative-room pathology cannot be obtained due to the necessity of decalcification.
  • In order to avoid multiple resections, an interim bridging with a reconstructive plate with a condylar head can be proposed before definitive graft reconstruction.
  • The prognosis of osteosarcoma of the mandible is better than that of long bones.
  • Chemotherapy or radiotherapy, which are very efficient for osteosarcoma in general, do not change the prognosis of osteosarcoma of the mandible.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Adult. Bone Transplantation. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Myxoma / diagnosis. Neoplasm Invasiveness. Prognosis. Radiography, Panoramic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17128192.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Uysal KM, Koyuncuoğlu M, Akman F, Güneri A, Sarialioğlu F, Kargi A, Olgun N, Manisali M: A rare tumor of craniofacial bones in children: a pediatric chondroblastic osteosarcoma case with diagnostic and therapeutic problems. Pediatr Hematol Oncol; 2001 Mar;18(2):147-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare tumor of craniofacial bones in children: a pediatric chondroblastic osteosarcoma case with diagnostic and therapeutic problems.
  • Osteosarcoma of the cranial facial region is uncommon and only rarely involves the ethmoid or sphenoid bones.
  • The authors report on an unusual case of a 17-year-old male presenting with chondroblastic osteosarcoma of the maxillary, ethmoid, and sphenoid sinuses who remains well and disease-free at 46 months.
  • He did not receive chemotherapy because of emerging hepatitis-B infection and vasculitis.
  • The literature on extragnathic craniofacial osteosarcomas is reviewed with particular emphasis on treatment options of this rare tumor.
  • [MeSH-major] Osteosarcoma / therapy. Skull Neoplasms / therapy
  • [MeSH-minor] Adolescent. Chondrocytes / pathology. Disease-Free Survival. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Humans. Magnetic Resonance Imaging. Male. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Maxillary Sinus Neoplasms / therapy. Sphenoid Sinus / pathology. Sphenoid Sinus / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11255734.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Lin JT, Yen CC, Wang WS, Chiou TJ, Liu JH, Wu HT, Chen PM: Case report: Unusual peritoneal spreading by metastatic osteosarcoma of the tibia. Br J Radiol; 2003 May;76(905):337-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Unusual peritoneal spreading by metastatic osteosarcoma of the tibia.
  • We report a 17-year-old boy with chondroblastic osteosarcoma initially found in left proximal tibia.
  • He received surgical resection and chemotherapy.
  • Despite intensive chemotherapy, the metastatic osteosarcoma of lung continued to invade the ribs and later into retroperitoneum and liver.
  • The metastatic pattern of chondroblastic osteosarcoma of tibia directly to the chest and then into the abdomen is unusual.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / secondary. Osteosarcoma / secondary. Tibia
  • [MeSH-minor] Adolescent. Humans. Liver Neoplasms / pathology. Male. Neoplasm Invasiveness. Retroperitoneal Neoplasms / pathology. Ribs. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12763950.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Ranen E, Dank G, Lavy E, Perl S, Lahav D, Orgad U: Oesophageal sarcomas in dogs: histological and clinical evaluation. Vet J; 2008 Oct;178(1):78-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumour types included osteosarcoma (47%), osteosarcoma with tumour giant cells (7%), fibroblastic osteosarcoma (13%), chondroblastic osteosarcoma (7%) fibrosarcoma (23%) and undifferentiated sarcoma (3%).
  • Histological grade evaluation revealed 33% grade 1 sarcoma, 50% grade 2 and 17% grade 3.
  • No correlation could be found between survival and signalment, duration of clinical signs, tumour type, tumour grade and chemotherapy.
  • Chemotherapy was found to reduce lung metastases' histological scores in three cases (P=0.0007).
  • Surgery seems to be the treatment of choice but the effect of chemotherapy warrants further investigation.
  • [MeSH-major] Dog Diseases / pathology. Esophageal Neoplasms / veterinary. Sarcoma / veterinary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804268.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Park HR, Min SK, Cho HD, Cho SJ, Lee JH, Lee Y, Park YK: Osteosarcoma of the ethmoid sinus. Skeletal Radiol; 2004 May;33(5):291-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of the ethmoid sinus.
  • A rare case of chondroblastic osteosarcoma arising from the ethmoid sinus is reported.
  • Biopsy revealed a chondroblastic osteosarcoma containing malignant chondroid elements and calcified malignant osteoid.
  • Treatment consisted of craniofacial resection followed by radiotherapy and chemotherapy with symptomatic improvement.
  • [MeSH-major] Bone Neoplasms / diagnosis. Chondrocytes / pathology. Ethmoid Sinus / pathology. Osteoblasts / pathology. Osteosarcoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy / methods. Female. Headache / etiology. Humans. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods. Vision Disorders / etiology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1971 Dec;122(6):719-25 [5288682.001]
  • [Cites] Am J Ophthalmol. 1952 Jun;35(6):811-8 [14923777.001]
  • [Cites] Cancer. 1990 Feb 15;65(4):1011-6 [2297650.001]
  • [Cites] Indian Pediatr. 1993 Feb;30(2):270-3 [8375897.001]
  • [Cites] Skeletal Radiol. 2003 Mar;32(3):161-4 [12605282.001]
  • [Cites] Head Neck. 1997 Sep;19(6):513-23 [9278760.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jun;99(6 Pt 1):489-90 [2350135.001]
  • [Cites] Arch Otolaryngol. 1979 Jun;105(6):358-9 [287437.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1973 Mar-Apr;82(2):162-5 [4512903.001]
  • [Cites] Otolaryngol Head Neck Surg. 1982 Jul-Aug;90(4):510-2 [6817286.001]
  • [Cites] J Laryngol Otol. 1988 Dec;102(12):1176-8 [3225534.001]
  • [Cites] Am J Surg. 1958 Oct;96(4):496-505 [13571537.001]
  • [Cites] Cancer. 1974 May;33(5):1289-305 [4207295.001]
  • [Cites] Mayo Clin Proc. 1983 Apr;58(4):268-72 [6572774.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jun;150(6):1397-402 [3259385.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):170-4 [9434826.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1956 Dec;65(4):914-36 [13403547.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Mar;18(2):147-52 [11255734.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] J Laryngol Otol. 1996 Jul;110(7):676-8 [8759546.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1288 [10789778.001]
  • [Cites] J Laryngol Otol. 1994 Nov;108(11):947-53 [7829947.001]
  • [Cites] Jibiinkoka. 1967 Aug;39(8):831-5 [5238840.001]
  • (PMID = 14985874.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Gerressen M, Donner A, Jundt G, Jänicke S, Smeets R, Riediger D, Ghassemi A: [High-grade osteosarcoma of the maxillary sinus. A case report]. Mund Kiefer Gesichtschir; 2006 Sep;10(5):347-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-grade osteosarcoma of the maxillary sinus. A case report].
  • BACKGROUND: Osteosarcoma of the jaw (JOS) constituting 5% to 13% of all osteosarcoma is a locally aggressive malignant mesenchymal tumor with high tendency to local recurrence and the ability to produce tumor osteoid.
  • Compared to osteosarcoma of the remaining skeleton (SOS) JOS metastasizes relatively rarely and relatively late.
  • CASE REPORT: The presented case deals with a 60-year-old male patient suffering from a newly occurred polypous mucosal tumor of the right-sided maxillary alveolar ridge bioptically diagnosed as a granulation tissue polyp first.
  • After transmaxillary resection of the tumor and consultation of a bone tumor reference center the final diagnosis of a high-grade chondroblastic osteosarcoma could be made.
  • After surgical reduction of the rapidly growing sarcoma chemotherapy according to the COOS/EURO-B.O.S.S. protocol was initiated at a stage when computed tomography showed diffuse metastatic disease to the lungs.
  • Chemotherapy could delay the progress of the disease only temporarily.
  • CONCLUSION: In JOS radical surgical resection is the therapy of first choice.
  • [MeSH-major] Alveolar Process / surgery. Maxillary Sinus Neoplasms / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Apr;91(4):445-51 [11312461.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2311-6 [6573939.001]
  • [Cites] J Craniomaxillofac Surg. 1991 Feb;19(2):90-3 [2037699.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):439-45 [2297634.001]
  • [Cites] Arch Otolaryngol. 1977 Aug;103(8):485-8 [267450.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Jul;60(1):56-60 [3862014.001]
  • [Cites] Quintessence Int. 2004 Mar;35(3):228-33 [15119682.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Oct;55(10):1177-81 [9331247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Jul;117(7):761-6 [1863442.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):56-61 [9001266.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):572-6 [6932821.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):374-6 [7719220.001]
  • [Cites] Am J Clin Pathol. 1970 Oct;54(4):625-36 [5273163.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Oct;72(4):444-8 [1923444.001]
  • [Cites] J Maxillofac Surg. 1978 Nov;6(4):273-6 [83344.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1555-63 [1893357.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5975-80 [12185601.001]
  • (PMID = 16947065.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Iwata A, Hirota T, Konno K, Fujimoto T, Sumida S, Sato K, Hara K: Osteosarcoma as a second malignancy after treatment for neuroblastoma. Pediatr Hematol Oncol; 2001 Oct-Nov;18(7):465-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma as a second malignancy after treatment for neuroblastoma.
  • Preoperative chemotherapy was given, followed by local surgical excision.
  • Postoperatively, irradiation of the tumor bed and adjuvant chemotherapy was given for 11 months.
  • Nine years after cessation of chemotherapy, the patient developed left hip-joint pain.
  • Biopsy of the ischium showed chondroblastic osteosarcoma.
  • Limb salvage surgery was performed after preoperative chemotherapy.
  • Postoperatively, adjuvant chemotherapy was given for 14 months.
  • Twenty-two months after treatment for the secondary osteosarcoma, the patient has been remained in disease-free condition without any evidence of relapse.
  • A second osteosarcoma occurring outside the radiation field after treatment for neuroblastoma is quite rare.
  • This unusual case emphasized the need for close monitoring for development of second malignant neoplasms in survivors of neuroblastoma even in the absence of a known predisposing factor, such as radiation therapy.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Neuroblastoma / therapy. Osteosarcoma / etiology
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Female. Hip Joint / pathology. Humans. Infant

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11594710.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Benjamin RS, Patel SR: Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res; 2009;152:355-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy.
  • Most data on osteosarcoma is derived from pediatric studies.
  • Although the majority of adult patients with osteosarcoma are young adults, who might be treated in a similar fashion, experience derived from a slightly older population is helpful in directing therapy.
  • We treated a series of 123 patients with osteosarcoma of the extremities with adriamycin and cisplatin as induction therapy.
  • Sequential addition of methotrexate and methotrexate plus ifosfamide in subsequent cohorts improved the continuous relapse-free survival of poor responders such that overall survival improvement was noted in the group where therapy was modified by adding both agents to those with <90% tumor necrosis.
  • Patients with chondroblastic osteosarcoma with poor necrosis had a trend towards improved continuous relapse-free survival compared with other patients with conventional osteosarcoma.
  • Histologic variants of osteosarcoma except telangiectatic osteosarcoma had a worse prognosis than those with conventional osteosarcoma.
  • The variants, especially dedifferentiated parosteal osteosarcoma and dedifferentiated well-differentiated intraosseous osteosarcoma are more common in adults than children, accounting for some of the inferior prognosis in adults.
  • Older patients obviously cannot tolerate the doses of therapy given to children and young adults, again decreasing the chances of successful treatment.
  • Patients with secondary osteosarcoma are often much older as are many with osteosarcomas of the pelvis and jaw.
  • An attempt to intensify therapy in poor-prognosis patients with a three-drug regimen of adriamycin, cisplatin, and ifosfamide with peripheral stem cell support was unsuccessful at prolonging relapse-free survival, and we no longer use that approach.
  • [MeSH-major] Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213401.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


22. Gadwal SR, Gannon FH, Fanburg-Smith JC, Becoskie EM, Thompson LD: Primary osteosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 22 cases with a review of the literature. Cancer; 2001 Feb 1;91(3):598-605
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 22 cases with a review of the literature.
  • No secondary sarcomas (radiation-induced or those arising after chemotherapy) or those associated with known syndromes were included.
  • All cases, except one chondroblastic osteosarcoma, were osteoblastic osteosarcomas.
  • Thirteen patients underwent initial surgical resection with (n = 5) or without (n = 9) additional radiation and/or chemotherapy.
  • The remaining 9 patients had an initial biopsy for diagnosis followed by surgery (n = 4) or surgery and radiation and/or chemotherapy (n = 5).
  • The 3 patients with high-grade osteosarcoma were alive without disease (mean, 20.0 yrs).
  • [MeSH-major] Bone Neoplasms / pathology. Head and Neck Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Outcome Assessment (Health Care)

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11169944.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 52
  •  go-up   go-down


23. McGuff HS, Heim-Hall J, Holsinger FC, Jones AA, O'Dell DS, Hafemeister AC: Maxillary osteosarcoma associated with a dental implant: report of a case and review of the literature regarding implant-related sarcomas. J Am Dent Assoc; 2008 Aug;139(8):1052-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maxillary osteosarcoma associated with a dental implant: report of a case and review of the literature regarding implant-related sarcomas.
  • The authors present the first reported case of a sarcoma arising in association with a dental implant.
  • CASE DESCRIPTION: A 38-year-old woman developed a low-grade chondroblastic osteosarcoma of the right maxilla 11 months after receiving a titanium dental implant.
  • She was treated with systemic chemotherapy and then a maxillary resection.
  • CLINICAL IMPLICATIONS: The use of endosseous implants has been associated with a low risk for the development of cancer.
  • [MeSH-major] Dental Implants, Single-Tooth / adverse effects. Maxillary Neoplasms / etiology. Osteosarcoma / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dental Materials / adverse effects. Female. Follow-Up Studies. Humans. Maxilla / surgery. Neoadjuvant Therapy. Palate, Hard / surgery. Titanium / adverse effects

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682619.001).
  • [ISSN] 0002-8177
  • [Journal-full-title] Journal of the American Dental Association (1939)
  • [ISO-abbreviation] J Am Dent Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dental Materials; D1JT611TNE / Titanium
  • [Number-of-references] 63
  •  go-up   go-down


24. Böhm P, Fritz J, Thiede S, Budach W: Reimplantation of extracorporeal irradiated bone segments in musculoskeletal tumor surgery: clinical experience in eight patients and review of the literature. Langenbecks Arch Surg; 2003 Jan;387(9-10):355-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All seven patients with high-grade tumors received chemotherapy.
  • One man with a chondroblastic osteosarcoma developed pulmonary metastases which were resected.
  • One woman with teleangiectatic osteosarcoma developed a local recurrence in the soft tissue without contact to the irradiated reimplant.
  • Another woman 67 months after IEIR for an osteosarcoma of the distal femur developed a subcutaneous metastasis of the scalp and the thoracic wall and an ossifying pulmonary metastasis.
  • At the time of writing she is receiving chemotherapy.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12536331.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


25. Wengerkievicz AC, Corá AP, de Almeida LP, Duarte NJ, Siqueira SA, Antonangelo L: Neoplastic ascites in osteosarcoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):845-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic ascites in osteosarcoma: a case report.
  • BACKGROUND: Osteosarcoma is a malignant tumor of connective tissue whose tumor cells produce bone tissue.
  • It can be classified as osteoblastic, chondroblastic, or fibroblastic, according to the predominant histologic type of cells.
  • We present a case of osteosarcoma with peritoneal dissemination that developed neoplastic ascites.
  • CASE: A 46-year-old patient came to the hospital with a 4-month history of lumbar pain and weakness in the lower limbs.
  • Computed tomography showed blastic lesions in the L3 vertebral body.
  • Surgical resection and histologic analysis revealed a mixed osteoblastic and chondroblastic osteosarcoma.
  • After only one session of chemotherapy, the patient presented a marked clinical worsening with extensive metastatic dissemination and occurrence of voluminous ascites.
  • CONCLUSION: This case is the only report of osteosarcoma primarily focused on the vertebral column affected by peritoneal metastasis shown by cytologic examination of ascitic fluid.
  • [MeSH-major] Ascites / pathology. Osteosarcoma / pathology. Spinal Neoplasms / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053553.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Wei-wei L, Qiu-liang W, Guo-hao W, Zhi-hua C, Zong-yuan Z: Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer. Laryngoscope; 2005 Sep;115(9):1574-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer.
  • OBJECTIVES: Postirradiation osteosarcoma (PIOS) arising after radiation of nasopharyngeal cancer (NPC) is rare and seldom reported.
  • METHODS: Fifteen patients with NPC were determined to have PIOS after reviewing 426 patients with osteogenic sarcomas.
  • Their clinical records, image and pathologic slides, and follow-up data after treatment were collected to perform analysis.
  • RESULTS: The incidence rate of PIOS in NPC was approximately 0.037% (15/40,719), which occupied approximately 3.5% (15/426) among all kinds of osteogenic sarcomas.
  • The latent time of PIOS after irradiation for NPC ranged from 4 to 27 years, with a mean of 13.3 years.
  • Radiologically, soft tissue mass, bone destruction, and tumor new bone formation were the main characteristics.
  • Pathologic subtypes included 53.3% (8/15) of fibroblastic osteosarcoma, 33.3% (5/15) of chondroblastic osteosarcoma, and 13.3% (2/15) of mixed type osteosarcoma.
  • The survival time after treatment for all patients ranged from 7 to 41 months, with a mean of 18 months.
  • Surgery combined with pre- and postoperative chemotherapy might be an effective way to improve survival.
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology. Middle Aged. Nasal Cavity. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148697.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement